Cyclerion Therapeutics, Inc.
CYCN
$3.28
$0.12083.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 41.92% | 51.03% | 110.43% | 100.39% | 88.06% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 102.30% | 102.35% | -429.18% | -336.73% | -282.04% |
| Change in Net Operating Assets | 66.57% | 78.65% | 40.95% | -527.89% | -61.44% |
| Cash from Operations | 79.60% | 76.69% | 61.47% | 50.27% | 47.69% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Investing | -- | -100.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 5,325.00% | 5,325.00% | 6,717.24% | 6,717.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | -- |
| Cash from Financing | -- | -100.00% | -100.00% | 17,224.14% | 17,224.14% |
| Foreign Exchange rate Adjustments | -175.00% | -116.67% | -122.22% | -40.00% | 166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 25.33% | 44.80% | 95.73% | 95.66% | 85.68% |